Description
t(8;21) RUNX1::RUNX1T1 Fusion Detection rRT-PCR Kit | RUNX1::RUNX1T1 Fusion Real-Time PCR Detection Kit
The chromosomal translocation t(8;21)(q22;q22) is one of the most common cytogenetic abnormalities in Acute Myeloid Leukemia (AML), particularly in the FAB-M2 subtype. This translocation results in the fusion of the RUNX1 (AML1) gene on chromosome 21 with the RUNX1T1 (ETO) gene on chromosome 8, creating the RUNX1::RUNX1T1 fusion. This fusion plays a key role in the pathogenesis of AML and disrupts the normal maturation of myeloid cells.
The presence of t(8;21) is usually associated with a relatively good prognosis and a favorable response to certain specific treatments. This abnormality accounts for approximately 7% of de novo AML cases and is more commonly observed in younger patients. In the AML-M2 subtype, approximately 20-40% of affected patients have this translocation. Additionally, t(8;21) has also been reported in cases of AML-M1, AML-M4, as well as therapy-related acute myeloid leukemia (t-AML).
Accurate detection of the RUNX1::RUNX1T1 fusion has significant clinical importance because it:
-
Facilitates patient prognosis assessment.
-
Plays a key role in treatment selection and monitoring of treatment response (MRD).
-
Enables rapid diagnosis in the acute phase of the disease and the implementation of effective treatment.
ap-rad, aiming to provide an accurate and efficient tool for the molecular diagnosis of hematology, has designed and manufactured the t(8;21) RUNX1::RUNX1T1 Fusion Detection rRT-PCR Kit. Utilizing rRT-PCR technology, this kit enables:
-
Rapid, sensitive, and highly specific detection of the RUNX1::RUNX1T1 fusion
-
Early detection of cytogenetic abnormalities in AML
-
Application in diagnosis, molecular interpretation, and treatment monitoring
for specialized laboratories, making it a reliable tool for the accurate diagnosis of AML based on t(8;21).
